Compounds > l 703606
Page last updated: 2024-09-25

l 703606

Description

L 703606: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID132629
CHEMBL ID24999
SCHEMBL ID15271416
MeSH IDM0206538

Synonyms (32)

Synonym
MLS002172464 ,
smr001254095
l-703,606
gtpl2104
(7r,8r)-7-[di(phenyl)methyl]-n-[(2-iodophenyl)methyl]-1-azabicyclo[2.2.2]octan-8-amine
l703606
l 703606
(cis)-n-(2-iodobenzyl)-2-benzhydrylquinuclidin-3-amine
bdbm50140771
((2r,3r)-2-benzhydryl-1-aza-bicyclo[2.2.2]oct-3-yl)-(2-iodo-benzyl)-amine
CHEMBL24999 ,
(cis)-2-(diphenylmethyl)-n-((2-iodophenyl)methyl)-1-azabicyclo(2.2.2)octan-3-amine
2-(diphenylmethyl)-n-((2-iodophenyl)methyl)-1-azabicyclo(2.2.2)octan-3-amine
144425-84-3
2-(diphenylmethyl)-n-((2-iodophenyl)methyl)-3-quinuclidinamine
l-703606
(i125)l-703606
(2r,3r)-2-benzhydryl-n-[(2-iodophenyl)methyl]-1-azabicyclo[2.2.2]octan-3-amine
1-azabicyclo(2.2.2)octan-3-amine, 2-(diphenylmethyl)-n-((2-iodophenyl)methyl)-, cis-
[(2r,3r)-2-benzhydrylquinuclidin-3-yl]-(2-iodobenzyl)amine;oxalic acid;hydrate
cid_25102597
(2r,3r)-2-benzhydryl-n-[(2-iodophenyl)methyl]-1-azabicyclo[2.2.2]octan-3-amine;oxalic acid;hydrate
(2r,3r)-2-(diphenylmethyl)-n-[(2-iodanylphenyl)methyl]-1-azabicyclo[2.2.2]octan-3-amine;ethanedioic acid;hydrate
bdbm79212
(2r,3r)-2-(diphenylmethyl)-n-[(2-iodophenyl)methyl]-1-azabicyclo[2.2.2]octan-3-amine;oxalic acid;hydrate
SCHEMBL15271416
DTXSID10162704
MLS-0412840
Q27078408
(2r,3r)-2-benzhydryl-n-(2-iodobenzyl)quinuclidin-3-amine
rel-(2r,3r)-2-benzhydryl-n-(2-iodobenzyl)quinuclidin-3-amine
SDCCGMLS-0412840.P031

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Substance-P receptorHomo sapiens (human)IC50 (µMol)0.00160.00000.09526.8130AID208276
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Substance-P receptorHomo sapiens (human)EC50 (µMol)0.02440.00010.00400.0244AID380505
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (38)

Processvia Protein(s)Taxonomy
aggressive behaviorSubstance-P receptorHomo sapiens (human)
positive regulation of leukocyte migrationSubstance-P receptorHomo sapiens (human)
angiotensin-mediated drinking behaviorSubstance-P receptorHomo sapiens (human)
inflammatory responseSubstance-P receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwaySubstance-P receptorHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationSubstance-P receptorHomo sapiens (human)
tachykinin receptor signaling pathwaySubstance-P receptorHomo sapiens (human)
long-term memorySubstance-P receptorHomo sapiens (human)
associative learningSubstance-P receptorHomo sapiens (human)
detection of abiotic stimulusSubstance-P receptorHomo sapiens (human)
response to ozoneSubstance-P receptorHomo sapiens (human)
positive regulation of epithelial cell migrationSubstance-P receptorHomo sapiens (human)
response to auditory stimulusSubstance-P receptorHomo sapiens (human)
regulation of smooth muscle cell migrationSubstance-P receptorHomo sapiens (human)
positive regulation of synaptic transmission, cholinergicSubstance-P receptorHomo sapiens (human)
positive regulation of synaptic transmission, GABAergicSubstance-P receptorHomo sapiens (human)
response to estradiolSubstance-P receptorHomo sapiens (human)
response to progesteroneSubstance-P receptorHomo sapiens (human)
response to nicotineSubstance-P receptorHomo sapiens (human)
operant conditioningSubstance-P receptorHomo sapiens (human)
sperm ejaculationSubstance-P receptorHomo sapiens (human)
eating behaviorSubstance-P receptorHomo sapiens (human)
positive regulation of vascular permeabilitySubstance-P receptorHomo sapiens (human)
response to ethanolSubstance-P receptorHomo sapiens (human)
positive regulation of action potentialSubstance-P receptorHomo sapiens (human)
positive regulation of blood pressureSubstance-P receptorHomo sapiens (human)
positive regulation of ossificationSubstance-P receptorHomo sapiens (human)
positive regulation of vasoconstrictionSubstance-P receptorHomo sapiens (human)
positive regulation of hormone secretionSubstance-P receptorHomo sapiens (human)
behavioral response to painSubstance-P receptorHomo sapiens (human)
regulation of smooth muscle cell proliferationSubstance-P receptorHomo sapiens (human)
positive regulation of lymphocyte proliferationSubstance-P receptorHomo sapiens (human)
positive regulation of epithelial cell proliferationSubstance-P receptorHomo sapiens (human)
positive regulation of stress fiber assemblySubstance-P receptorHomo sapiens (human)
response to electrical stimulusSubstance-P receptorHomo sapiens (human)
smooth muscle contraction involved in micturitionSubstance-P receptorHomo sapiens (human)
positive regulation of uterine smooth muscle contractionSubstance-P receptorHomo sapiens (human)
positive regulation of flagellated sperm motilitySubstance-P receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (3)

Processvia Protein(s)Taxonomy
tachykinin receptor activitySubstance-P receptorHomo sapiens (human)
protein bindingSubstance-P receptorHomo sapiens (human)
substance P receptor activitySubstance-P receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (7)

Processvia Protein(s)Taxonomy
plasma membraneSubstance-P receptorHomo sapiens (human)
cell surfaceSubstance-P receptorHomo sapiens (human)
dendriteSubstance-P receptorHomo sapiens (human)
sperm flagellumSubstance-P receptorHomo sapiens (human)
cell bodySubstance-P receptorHomo sapiens (human)
sperm headSubstance-P receptorHomo sapiens (human)
sperm midpieceSubstance-P receptorHomo sapiens (human)
plasma membraneSubstance-P receptorHomo sapiens (human)
sperm midpieceSubstance-P receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (36)

Assay IDTitleYearJournalArticle
AID208276Binding affinity against human Tachykinin receptor 1 expressed in astrocytoma UC11MG cells using [125I]- SP radioligand2004Journal of medicinal chemistry, Mar-11, Volume: 47, Issue:6
A non-peptide NK1 receptor agonist showing subpicomolar affinity.
AID1628462Intrinsic antimalarial activity against intermediate chloroquine-resistant Plasmodium falciparum 7G8 isolate MRA-154 harboring CRT SVMNT haplotype mutant assessed as reduction in parasite viability at 500 nM2016European journal of medicinal chemistry, Aug-25, Volume: 119Overcoming chloroquine resistance in malaria: Design, synthesis and structure-activity relationships of novel chemoreversal agents.
AID1628459Inhibition of CRT K76T mutant in chloroquine/artemisinin-resistant Plasmodium falciparum NHP4773 assessed as reversal of chloroquine resistance by measuring reduction in chloroquine IC50 at 500 nM relative to chloroquine alone2016European journal of medicinal chemistry, Aug-25, Volume: 119Overcoming chloroquine resistance in malaria: Design, synthesis and structure-activity relationships of novel chemoreversal agents.
AID1628457Inhibition of CRT K76T mutant in chloroquine/artemisinin-resistant Plasmodium falciparum ARS272 assessed as reversal of chloroquine resistance by measuring reduction in chloroquine IC50 at 500 nM relative to chloroquine alone2016European journal of medicinal chemistry, Aug-25, Volume: 119Overcoming chloroquine resistance in malaria: Design, synthesis and structure-activity relationships of novel chemoreversal agents.
AID208262Inhibition of labeled SP total binding to human Tachykinin receptor 1 expressed in astrocytoma UC11MG cells2004Journal of medicinal chemistry, Mar-11, Volume: 47, Issue:6
A non-peptide NK1 receptor agonist showing subpicomolar affinity.
AID1628467Intrinsic antimalarial activity against chloroquine-resistant Plasmodium falciparum NHP4559 harboring CRT K76T mutant assessed as reduction in parasite viability at 500 nM2016European journal of medicinal chemistry, Aug-25, Volume: 119Overcoming chloroquine resistance in malaria: Design, synthesis and structure-activity relationships of novel chemoreversal agents.
AID1628465Intrinsic antimalarial activity against chloroquine/artemisinin-resistant Plasmodium falciparum ARS233 harboring CRT K76T mutant assessed as reduction in parasite viability at 500 nM2016European journal of medicinal chemistry, Aug-25, Volume: 119Overcoming chloroquine resistance in malaria: Design, synthesis and structure-activity relationships of novel chemoreversal agents.
AID1628460Intrinsic antimalarial activity against chloroquine-sensitive Plasmodium falciparum 3D7 isolate MRA-102 assessed as reduction in parasite viability at 500 nM2016European journal of medicinal chemistry, Aug-25, Volume: 119Overcoming chloroquine resistance in malaria: Design, synthesis and structure-activity relationships of novel chemoreversal agents.
AID1628478Cytotoxicity against TAMH assessed as reduction in cell viability by CellTiter-Glo assay2016European journal of medicinal chemistry, Aug-25, Volume: 119Overcoming chloroquine resistance in malaria: Design, synthesis and structure-activity relationships of novel chemoreversal agents.
AID1628463Intrinsic antimalarial activity against chloroquine-resistant Plasmodium falciparum K1 isolate MRA-159 harboring CRT CVIET haplotype mutant assessed as reduction in parasite viability at 500 nM2016European journal of medicinal chemistry, Aug-25, Volume: 119Overcoming chloroquine resistance in malaria: Design, synthesis and structure-activity relationships of novel chemoreversal agents.
AID1628479Cytotoxicity against human AC10 cells assessed as reduction in cell viability by CellTiter-Glo assay2016European journal of medicinal chemistry, Aug-25, Volume: 119Overcoming chloroquine resistance in malaria: Design, synthesis and structure-activity relationships of novel chemoreversal agents.
AID1628453Inhibition of CRT SVMNT haplotype mutant in intermediate chloroquine-resistant Plasmodium falciparum 7G8 isolate MRA-154 t assessed as reversal of chloroquine resistance by measuring reduction in chloroquine IC50 at 500 nM relative to chloroquine alone2016European journal of medicinal chemistry, Aug-25, Volume: 119Overcoming chloroquine resistance in malaria: Design, synthesis and structure-activity relationships of novel chemoreversal agents.
AID1628484Permeability of compound incubated for 16 hrs at pH 7.4 by PAMPA2016European journal of medicinal chemistry, Aug-25, Volume: 119Overcoming chloroquine resistance in malaria: Design, synthesis and structure-activity relationships of novel chemoreversal agents.
AID1628485Inhibition of CRT CVIET haplotype mutant in Plasmodium falciparum K1 isolate MRA-159 infected in erythrocytes assessed as reversal of chloroquine resistance by measuring reduction in chloroquine IC50 by Hoechst 33342 staining based flow cytometry2016European journal of medicinal chemistry, Aug-25, Volume: 119Overcoming chloroquine resistance in malaria: Design, synthesis and structure-activity relationships of novel chemoreversal agents.
AID1628449Inhibition of CRT CVIET haplotype mutant in Plasmodium falciparum K1 isolate MRA-159 infected in erythrocytes assessed as chloroquine-coumarin probe accumulation at 10 uM after 10 hrs by Hoechst 33342 staining based flow cytometry (Rvb = 35.57 +/- 3.84%)2016European journal of medicinal chemistry, Aug-25, Volume: 119Overcoming chloroquine resistance in malaria: Design, synthesis and structure-activity relationships of novel chemoreversal agents.
AID1628458Inhibition of CRT K76T mutant in chloroquine-resistant Plasmodium falciparum NHP4559 assessed as reversal of chloroquine resistance by measuring reduction in chloroquine IC50 at 500 nM relative to chloroquine alone2016European journal of medicinal chemistry, Aug-25, Volume: 119Overcoming chloroquine resistance in malaria: Design, synthesis and structure-activity relationships of novel chemoreversal agents.
AID1628475Cytotoxicity against TAMH assessed as chloroquine IC50 by measuring reduction in cell viability at 100 nM by CellTiter-Glo assay (Rvb = 85.26 +/- 3.01 uM)2016European journal of medicinal chemistry, Aug-25, Volume: 119Overcoming chloroquine resistance in malaria: Design, synthesis and structure-activity relationships of novel chemoreversal agents.
AID1628481Therapeutic index, ratio of IC50 for human AC10 cells to EC50 for chloroquine-resistant Plasmodium falciparum K1 isolate MRA-159 CRT CVIET haplotype mutant2016European journal of medicinal chemistry, Aug-25, Volume: 119Overcoming chloroquine resistance in malaria: Design, synthesis and structure-activity relationships of novel chemoreversal agents.
AID1628468Intrinsic antimalarial activity against chloroquine/artemisinin-resistant Plasmodium falciparum NHP4773 harboring CRT K76T mutant assessed as reduction in parasite viability at 500 nM2016European journal of medicinal chemistry, Aug-25, Volume: 119Overcoming chloroquine resistance in malaria: Design, synthesis and structure-activity relationships of novel chemoreversal agents.
AID1628483Permeability of compound incubated for 6 hrs at pH 7.4 by PAMPA2016European journal of medicinal chemistry, Aug-25, Volume: 119Overcoming chloroquine resistance in malaria: Design, synthesis and structure-activity relationships of novel chemoreversal agents.
AID1628470Resistance index, ratio of chloroquine IC50 for chloroquine-resistant Plasmodium falciparum K1 isolate MRA-159 CRT CVIET haplotype mutant to chloroquine IC50 for chloroquine-sensitive Plasmodium falciparum 3D7 isolate MRA-102 at 500 nM2016European journal of medicinal chemistry, Aug-25, Volume: 119Overcoming chloroquine resistance in malaria: Design, synthesis and structure-activity relationships of novel chemoreversal agents.
AID1628464Intrinsic antimalarial activity against chloroquine-resistant Plasmodium falciparum Dd2 isolate MRA-156 harboring CRT K76T mutant assessed as reduction in parasite viability at 500 nM2016European journal of medicinal chemistry, Aug-25, Volume: 119Overcoming chloroquine resistance in malaria: Design, synthesis and structure-activity relationships of novel chemoreversal agents.
AID1628476Cytotoxicity against TAMH assessed as chloroquine IC50 by measuring reduction in cell viability at 1 uM by CellTiter-Glo assay (Rvb = 85.26 +/- 3.01 uM)2016European journal of medicinal chemistry, Aug-25, Volume: 119Overcoming chloroquine resistance in malaria: Design, synthesis and structure-activity relationships of novel chemoreversal agents.
AID1628482Aqueous kinetic solubility of compound in pH 7.4 solution incubated for 24 hrs2016European journal of medicinal chemistry, Aug-25, Volume: 119Overcoming chloroquine resistance in malaria: Design, synthesis and structure-activity relationships of novel chemoreversal agents.
AID1628461Intrinsic antimalarial activity against chloroquine-sensitive Plasmodium falciparum HB3 isolate MRA-155 assessed as reduction in parasite viability at 500 nM2016European journal of medicinal chemistry, Aug-25, Volume: 119Overcoming chloroquine resistance in malaria: Design, synthesis and structure-activity relationships of novel chemoreversal agents.
AID1628455Inhibition of CRT K76T mutant in chloroquine-resistant Plasmodium falciparum Dd2 isolate MRA-156 assessed as reversal of chloroquine resistance by measuring reduction in chloroquine IC50 at 500 nM relative to chloroquine alone2016European journal of medicinal chemistry, Aug-25, Volume: 119Overcoming chloroquine resistance in malaria: Design, synthesis and structure-activity relationships of novel chemoreversal agents.
AID1628451Potentiation of chloroquine-induced antimalarial activity against chloroquine-sensitive Plasmodium falciparum 3D7 isolate MRA-102 assessed as reduction in chloroquine IC50 at 500 nM relative to chloroquine alone2016European journal of medicinal chemistry, Aug-25, Volume: 119Overcoming chloroquine resistance in malaria: Design, synthesis and structure-activity relationships of novel chemoreversal agents.
AID1628454Inhibition of CRT CVIET haplotype mutant in chloroquine-resistant Plasmodium falciparum K1 isolate MRA-159 assessed as reversal of chloroquine resistance by measuring reduction in chloroquine IC50 at 500 nM relative to chloroquine alone2016European journal of medicinal chemistry, Aug-25, Volume: 119Overcoming chloroquine resistance in malaria: Design, synthesis and structure-activity relationships of novel chemoreversal agents.
AID1628456Inhibition of CRT K76T mutant in chloroquine/artemisinin-resistant Plasmodium falciparum ARS233 assessed as reversal of chloroquine resistance by measuring reduction in chloroquine IC50 at 500 nM relative to chloroquine alone2016European journal of medicinal chemistry, Aug-25, Volume: 119Overcoming chloroquine resistance in malaria: Design, synthesis and structure-activity relationships of novel chemoreversal agents.
AID380505Displacement of [3H]SR140333 from human recombinant NK1 receptor expressed in CHO cells2006Journal of natural products, Mar, Volume: 69, Issue:3
Alkaloids from Eschscholzia californica and their capacity to inhibit binding of [3H]8-Hydroxy-2-(di-N-propylamino)tetralin to 5-HT1A receptors in Vitro.
AID1628466Intrinsic antimalarial activity against chloroquine/artemisinin-resistant Plasmodium falciparum ARS272 harboring CRT K76T mutant assessed as reduction in parasite viability at 500 nM2016European journal of medicinal chemistry, Aug-25, Volume: 119Overcoming chloroquine resistance in malaria: Design, synthesis and structure-activity relationships of novel chemoreversal agents.
AID1628469Resistance index, ratio of chloroquine IC50 for intermediate chloroquine-resistant Plasmodium falciparum 7G8 isolate MRA-154 CRT SVMNT haplotype mutant to chloroquine IC50 for chloroquine-sensitive Plasmodium falciparum 3D7 isolate MRA-102 at 500 nM2016European journal of medicinal chemistry, Aug-25, Volume: 119Overcoming chloroquine resistance in malaria: Design, synthesis and structure-activity relationships of novel chemoreversal agents.
AID1628477Cytotoxicity against TAMH assessed as chloroquine IC50 by measuring reduction in cell viability at 10 uM by CellTiter-Glo assay (Rvb = 85.26 +/- 3.01 uM)2016European journal of medicinal chemistry, Aug-25, Volume: 119Overcoming chloroquine resistance in malaria: Design, synthesis and structure-activity relationships of novel chemoreversal agents.
AID1628452Potentiation of chloroquine-induced antimalarial activity against chloroquine-sensitive Plasmodium falciparum HB3 isolate MRA-155 assessed as reduction in chloroquine IC50 at 500 nM relative to chloroquine alone2016European journal of medicinal chemistry, Aug-25, Volume: 119Overcoming chloroquine resistance in malaria: Design, synthesis and structure-activity relationships of novel chemoreversal agents.
AID1628480Therapeutic index, ratio of IC50 for TAMH to EC50 for chloroquine-resistant Plasmodium falciparum K1 isolate MRA-159 CRT CVIET haplotype mutant2016European journal of medicinal chemistry, Aug-25, Volume: 119Overcoming chloroquine resistance in malaria: Design, synthesis and structure-activity relationships of novel chemoreversal agents.
AID1346346Human NK1 receptor (Tachykinin receptors)1996The Journal of biological chemistry, Aug-23, Volume: 271, Issue:34
The unpredicted high affinities of a large number of naturally occurring tachykinins for chimeric NK1/NK3 receptors suggest a role for an inhibitory domain in determining receptor specificity.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (74)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's14 (18.92)18.2507
2000's44 (59.46)29.6817
2010's16 (21.62)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other74 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceDescriptionRelationhip StrengthStudiesTrialsClassesRoles
mezlocillin[no description available]medium10
senktide[no description available]medium20
sr 142806[no description available]medium10
eledoisin[no description available]medium10peptide
substance p[no description available]medium480peptideneurokinin-1 receptor agonist;
neurotransmitter;
vasodilator agent
methiothepin[no description available]medium10aryl sulfide;
dibenzothiepine;
N-alkylpiperazine;
tertiary amino compound		antipsychotic agent;
dopaminergic antagonist;
geroprotector;
serotonergic antagonist
pyrilamine[no description available]medium20aromatic ether;
ethylenediamine derivative		H1-receptor antagonist
yohimbine[no description available]medium10methyl 17-hydroxy-20xi-yohimban-16-carboxylatealpha-adrenergic antagonist;
dopamine receptor D2 antagonist;
serotonergic antagonist
n-methyllaurotetanine[no description available]medium10
metergoline[no description available]medium10carbamate ester;
ergoline alkaloid		dopamine agonist;
geroprotector;
serotonergic antagonist
phenylisopropyladenosine[no description available]medium10aromatic amine;
benzenes;
hydrocarbyladenosine;
purine nucleoside;
secondary amino compound		adenosine A1 receptor agonist;
neuroprotective agent
neurokinin a(4-10), tyr(5)-trp(6,8,9)-lys(10)-[no description available]medium40
pseudoprotopine[no description available]medium10
quercetin[no description available]medium107-hydroxyflavonol;
pentahydroxyflavone		antibacterial agent;
antineoplastic agent;
antioxidant;
Aurora kinase inhibitor;
chelator;
EC 1.10.99.2 [ribosyldihydronicotinamide dehydrogenase (quinone)] inhibitor;
geroprotector;
phytoestrogen;
plant metabolite;
protein kinase inhibitor;
radical scavenger
rutin[no description available]medium10disaccharide derivative;
quercetin O-glucoside;
rutinoside;
tetrahydroxyflavone		antioxidant;
metabolite
(3r)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone[no description available]medium10morpholines;
naphthyl ketone;
organic heterotricyclic compound;
synthetic cannabinoid		analgesic;
apoptosis inhibitor;
neuroprotective agent
narcissin flavonol[no description available]medium10disaccharide derivative;
glycosyloxyflavone;
monomethoxyflavone;
trihydroxyflavone
sincalide[no description available]medium10oligopeptide
octoclothepine[no description available]medium10dibenzothiepine
desipramine[no description available]medium10dibenzoazepine;
secondary amino compound		adrenergic uptake inhibitor;
alpha-adrenergic antagonist;
antidepressant;
cholinergic antagonist;
drug allergen;
EC 3.1.4.12 (sphingomyelin phosphodiesterase) inhibitor;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
H1-receptor antagonist;
serotonin uptake inhibitor
loperamide[no description available]medium10monocarboxylic acid amide;
monochlorobenzenes;
piperidines;
tertiary alcohol		anticoronaviral agent;
antidiarrhoeal drug;
mu-opioid receptor agonist
4-(4-chlorophenyl)-4-hydroxypiperidine[no description available]medium10piperidines
fenpipramide[no description available]medium10
quinuclidines[no description available]medium700quinuclidines;
saturated organic heterobicyclic parent
mocetinostat[no description available]medium20aminopyrimidine;
benzamides;
pyridines;
secondary amino compound;
secondary carboxamide;
substituted aniline		antineoplastic agent;
apoptosis inducer;
autophagy inducer;
cardioprotective agent;
EC 3.5.1.98 (histone deacetylase) inhibitor;
hepatotoxic agent
way 100135[no description available]medium20piperazines
hc 030031[no description available]medium20
allyl isothiocyanate[no description available]medium10alkenyl isothiocyanate;
isothiocyanate		antimicrobial agent;
antineoplastic agent;
apoptosis inducer;
lachrymator;
metabolite
p-methoxy-n-methylphenethylamine[no description available]medium10aromatic ether;
secondary amino compound		metabolite
histamine[no description available]medium10aralkylamino compound;
imidazoles		human metabolite;
mouse metabolite;
neurotransmitter
dizocilpine maleate[no description available]medium30maleate salt;
tetracyclic antidepressant		anaesthetic;
anticonvulsant;
neuroprotective agent;
nicotinic antagonist;
NMDA receptor antagonist
serine[no description available]medium10L-alpha-amino acid;
proteinogenic amino acid;
serine family amino acid;
serine zwitterion;
serine		algal metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
cobalt[no description available]medium30cobalt group element atom;
metal allergen		micronutrient
cobaltous chloride[no description available]medium30cobalt salt;
inorganic chloride		allergen;
calcium channel blocker;
sensitiser;
two-colour indicator
carbachol[no description available]medium40ammonium salt;
carbamate ester		cardiotonic drug;
miotic;
muscarinic agonist;
nicotinic acetylcholine receptor agonist;
non-narcotic analgesic
piperidines[no description available]medium50
l 733060[no description available]medium20piperidines
capsaicin[no description available]medium120capsaicinoidnon-narcotic analgesic;
TRPV1 agonist;
voltage-gated sodium channel blocker
galantide[no description available]medium10
ceruletide[no description available]medium10oligopeptidediagnostic agent;
gastrointestinal drug
naltrexone[no description available]medium10cyclopropanes;
morphinane-like compound;
organic heteropentacyclic compound		antidote to opioid poisoning;
central nervous system depressant;
environmental contaminant;
mu-opioid receptor antagonist;
xenobiotic
morphine[no description available]medium10morphinane alkaloid;
organic heteropentacyclic compound;
tertiary amino compound		anaesthetic;
drug allergen;
environmental contaminant;
geroprotector;
mu-opioid receptor agonist;
opioid analgesic;
plant metabolite;
vasodilator agent;
xenobiotic
pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid[no description available]medium10arenesulfonic acid;
azobenzenes;
methylpyridines;
monohydroxypyridine;
organic phosphate;
pyridinecarbaldehyde		purinergic receptor P2X antagonist
adenosine diphosphate[no description available]medium10adenosine 5'-phosphate;
purine ribonucleoside 5'-diphosphate		fundamental metabolite;
human metabolite
cadmium[no description available]medium10cadmium molecular entity;
zinc group element atom
tetrodotoxin[no description available]medium10azatetracycloalkane;
oxatetracycloalkane;
quinazoline alkaloid		animal metabolite;
bacterial metabolite;
marine metabolite;
neurotoxin;
voltage-gated sodium channel blocker
pyridoxal phosphate[no description available]medium10methylpyridines;
monohydroxypyridine;
pyridinecarbaldehyde;
vitamin B6 phosphate		coenzyme;
cofactor;
EC 2.7.7.7 (DNA-directed DNA polymerase) inhibitor;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
fenamic acid[no description available]medium10aminobenzoic acid;
secondary amino compound		membrane transport modulator
formaldehyde[no description available]medium10aldehyde;
one-carbon compound		allergen;
carcinogenic agent;
disinfectant;
EC 3.5.1.4 (amidase) inhibitor;
environmental contaminant;
Escherichia coli metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
colforsin[no description available]medium10acetate ester;
cyclic ketone;
labdane diterpenoid;
organic heterotricyclic compound;
tertiary alpha-hydroxy ketone;
triol		adenylate cyclase agonist;
anti-HIV agent;
antihypertensive agent;
plant metabolite;
platelet aggregation inhibitor;
protein kinase A agonist
4,4'-diisothiocyanostilbene-2,2'-disulfonic acid[no description available]medium10
capsazepine[no description available]medium40benzazepine;
catechols;
monochlorobenzenes;
thioureas		capsaicin receptor antagonist
chlorine[no description available]medium20halide anion;
monoatomic chlorine		cofactor;
Escherichia coli metabolite;
human metabolite
rmi 12330a[no description available]medium10
transforming growth factor beta[no description available]medium10
resiniferatoxin[no description available]medium20carboxylic ester;
diterpenoid;
enone;
monomethoxybenzene;
organic heteropentacyclic compound;
ortho ester;
phenols;
tertiary alpha-hydroxy ketone		analgesic;
neurotoxin;
plant metabolite;
TRPV1 agonist
nickel[no description available]medium10metal allergen;
nickel group element atom		epitope;
micronutrient
2-amino-5-phosphonovalerate[no description available]medium30non-proteinogenic alpha-amino acidNMDA receptor antagonist
valine[no description available]medium10L-alpha-amino acid zwitterion;
L-alpha-amino acid;
proteinogenic amino acid;
pyruvate family amino acid;
valine		algal metabolite;
Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
Saccharomyces cerevisiae metabolite
calciseptine[no description available]medium10
omega-agatoxin iva[no description available]medium10
ly 274614[no description available]medium10
glycine[no description available]medium10alpha-amino acid;
amino acid zwitterion;
proteinogenic amino acid;
serine family amino acid		EC 2.1.2.1 (glycine hydroxymethyltransferase) inhibitor;
fundamental metabolite;
hepatoprotective agent;
micronutrient;
neurotransmitter;
NMDA receptor agonist;
nutraceutical
glutamic acid[no description available]medium30glutamic acid;
glutamine family amino acid;
L-alpha-amino acid;
proteinogenic amino acid		Escherichia coli metabolite;
ferroptosis inducer;
micronutrient;
mouse metabolite;
neurotransmitter;
nutraceutical
alpha-methyl-4-carboxyphenylglycine[no description available]medium10non-proteinogenic alpha-amino acidmetabotropic glutamate receptor antagonist
2,3-dioxo-6-nitro-7-sulfamoylbenzo(f)quinoxaline[no description available]medium10naphthalenes;
sulfonic acid derivative
quinoxalines[no description available]medium20mancude organic heterobicyclic parent;
naphthyridine;
ortho-fused heteroarene
6-methyl-2-(phenylethynyl)pyridine[no description available]medium10acetylenic compound;
methylpyridines		anxiolytic drug;
metabotropic glutamate receptor antagonist
neurokinin a[no description available]medium60
6-cyano-7-nitroquinoxaline-2,3-dione[no description available]medium30quinoxaline derivative
cyclo(gln-trp-phe-gly-leu-met)[no description available]medium20
pyrrolidonecarboxylic acid[no description available]medium505-oxoproline;
L-proline derivative;
non-proteinogenic L-alpha-amino acid		algal metabolite
substance p (6-11)[no description available]medium30
dinitrochlorobenzene[no description available]medium10C-nitro compound;
monochlorobenzenes		allergen;
epitope;
sensitiser
acetic acid[no description available]medium10monocarboxylic acidantimicrobial food preservative;
Daphnia magna metabolite;
food acidity regulator;
protic solvent
tubocurarine[no description available]medium10bisbenzylisoquinoline alkaloiddrug allergen;
muscle relaxant;
nicotinic antagonist
pd 98059[no description available]medium10aromatic amine;
monomethoxyflavone		EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor;
geroprotector
sr 48968[no description available]medium10
dinoprostone[no description available]medium10prostaglandins Ehuman metabolite;
mouse metabolite;
oxytocic
sb 202190[no description available]medium10imidazoles;
organofluorine compound;
phenols;
pyridines		apoptosis inducer;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
6-ketoprostaglandin f1 alpha[no description available]medium10prostaglandins Falphahuman metabolite;
mouse metabolite
ro 31-8220[no description available]medium10imidothiocarbamic ester;
indoles;
maleimides		EC 2.7.11.13 (protein kinase C) inhibitor
phorbol 12,13-dibutyrate[no description available]medium10butyrate ester;
phorbol ester;
tertiary alpha-hydroxy ketone
tacrolimus[no description available]medium10macrolide lactambacterial metabolite;
immunosuppressive agent
nimodipine[no description available]medium102-methoxyethyl ester;
C-nitro compound;
dicarboxylic acids and O-substituted derivatives;
diester;
dihydropyridine;
isopropyl ester		antihypertensive agent;
calcium channel blocker;
cardiovascular drug;
vasodilator agent
gr 82334[no description available]medium10
physalaemin[no description available]medium10
lidocaine[no description available]medium10benzenes;
monocarboxylic acid amide;
tertiary amino compound		anti-arrhythmia drug;
drug allergen;
environmental contaminant;
local anaesthetic;
xenobiotic
gamma-aminobutyric acid[no description available]medium10amino acid zwitterion;
gamma-amino acid;
monocarboxylic acid		human metabolite;
neurotransmitter;
Saccharomyces cerevisiae metabolite;
signalling molecule
corticosterone[no description available]medium1011beta-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(4) steroid;
C21-steroid;
glucocorticoid;
primary alpha-hydroxy ketone		human metabolite;
mouse metabolite
hydrogen sulfide[no description available]medium10gas molecular entity;
hydracid;
mononuclear parent hydride;
sulfur hydride		Escherichia coli metabolite;
genotoxin;
metabolite;
signalling molecule;
toxin;
vasodilator agent
sodium bisulfide[no description available]medium10
7,7-diphenyl-2-(1-imino-2-(2-methoxyphenyl)ethyl)perhydroisoindol-4-one[no description available]medium20
histidine[no description available]medium10amino acid zwitterion;
histidine;
L-alpha-amino acid;
polar amino acid zwitterion;
proteinogenic amino acid		algal metabolite;
Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
Saccharomyces cerevisiae metabolite
tryptophan[no description available]medium10erythrose 4-phosphate/phosphoenolpyruvate family amino acid;
L-alpha-amino acid zwitterion;
L-alpha-amino acid;
proteinogenic amino acid;
tryptophan zwitterion;
tryptophan		antidepressant;
Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
plant metabolite;
Saccharomyces cerevisiae metabolite
3,5-bis(trifluoromethyl)benzyl n-acetyltryptophan[no description available]medium10
septide[no description available]medium20
fluorescein[no description available]medium102-benzofurans;
gamma-lactone;
organic heteropentacyclic compound;
oxaspiro compound;
polyphenol;
xanthene dye		fluorescent dye;
radioopaque medium
lysine[no description available]medium10aspartate family amino acid;
L-alpha-amino acid zwitterion;
L-alpha-amino acid;
lysine;
organic molecular entity;
proteinogenic amino acid		algal metabolite;
anticonvulsant;
Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
plant metabolite;
Saccharomyces cerevisiae metabolite
erythrosine[no description available]medium10
cp 96345[no description available]medium20
phosphoramidon[no description available]medium10deoxyaldohexose phosphate;
dipeptide		bacterial metabolite;
EC 3.4.24.11 (neprilysin) inhibitor;
EC 3.4.24.71 (endothelin-converting enzyme 1) inhibitor
captopril[no description available]medium10alkanethiol;
L-proline derivative;
N-acylpyrrolidine;
pyrrolidinemonocarboxylic acid		antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
substance p, sar(9)-met(o2)(11)-[no description available]medium20
sr 140333[no description available]medium20
substance p, methyl ester-[no description available]medium10
n-methylaspartate[no description available]medium10amino dicarboxylic acid;
D-alpha-amino acid;
D-aspartic acid derivative;
secondary amino compound		neurotransmitter agent
alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid[no description available]medium10non-proteinogenic alpha-amino acid
fg 9041[no description available]medium10quinoxaline derivative
iturelix[no description available]medium10
egtazic acid[no description available]medium10diether;
tertiary amino compound;
tetracarboxylic acid		chelator
substance p[no description available]medium10
interleukin-8[no description available]medium10
neurokinin b[no description available]medium10polypeptide
guanylyl imidodiphosphate[no description available]medium10nucleoside triphosphate analogue
substance p, tyr(8)-[no description available]medium10
ConditionIndicatedRelationship StrengthStudiesTrials
Ache0low100
Acute Edematous Pancreatitis0low10
Acute Pancreatitis0low10
Age-Related Osteoporosis0low20
Aggression0low10
Alcohol Abuse0low10
Alcohol Addiction0low10
Alcohol Dependence0low10
Alcohol Drinking0low10
Alcohol Use Disorder0low10
Alcoholic Intoxication, Chronic0low10
Alcoholism0low10
Allodynia0low70
Allodynia, Mechanical0low70
Allodynia, Tactile0low70
Allodynia, Thermal0low70
Anasarca0low80
Anxiety0low10
Arthritis0low10
Blood Poisoning0low10
Bloodstream Infection0low10
Body Weight0low20
Bone Loss, Age-Related0low20
Bowel Diseases, Inflammatory0low10
Brain Ischemia0low10
Burns0low30
Central Nervous System Lyme Disease0low10
Cerebral Ischemia0low10
Contact Dermatitis0low10
Deficiency, Magnesium0low20
Dermatitis Venenata0low10
Dermatitis, Contact0low10
Dermatoses0low10
Dermatosis0low10
Disease Models, Animal0low60
Dropsy0low80
Eczema, Contact0low10
Edema0low80
Encephalopathy, Ischemic0low10
Encephalopathy, Lyme Disease0low10
Ethanol Abuse0low10
Hydrops0low80
Hyperalgesia0low70
Hyperalgesia, Mechanical0low70
Hyperalgesia, Primary0low70
Hyperalgesia, Secondary0low70
Hyperalgesia, Tactile0low70
Hyperalgesia, Thermal0low70
Hyperalgesic Sensations0low70
Hyperalgia0low70
Hyperalgia, Mechanical0low70
Hyperalgia, Primary0low70
Hyperalgia, Secondary0low70
Hypercapnia0low10
Hypersensitivity, Contact0low10
Inflammation0low20
Inflammatory Bowel Diseases0low10
Injuries, Spinal Cord0low20
Injury, Myocardial Reperfusion0low10
Innate Inflammatory Response0low20
Ischemia, Cerebral0low10
Ischemic Encephalopathy0low10
Itching0low20
Lesion of Sciatic Nerve0low10
Lyme Borreliosis, Nervous System0low10
Lyme Disease Encephalopathy0low10
Lyme Disease Mononeuritis Multiplex0low10
Lyme Disease, Central Nervous System0low10
Lyme Disease, Nervous System0low10
Lyme Meningoencephalitis0low10
Lyme Meningoradiculitis0low10
Lyme Neuroborreliosis0low10
Lyme Polyradiculitis0low10
Lyme Polyradiculopathy0low10
Magnesium Deficiency0low20
Mechanical Allodynia0low70
Mechanical Hyperalgesia0low70
Meningoencephalitis, Lyme0low10
Mononeuritis Multiplex, Lyme Disease0low10
Muscle Contraction0low10
Myelopathy, Traumatic0low20
Myocardial Ischemic Reperfusion Injury0low10
Myocardial Reperfusion Injury0low10
Nerve Pain0low10
Nervous System Lyme Borreliosis0low10
Nervous System Lyme Disease0low10
Neuralgia0low10
Neuralgia-Neuritis, Sciatic Nerve0low10
Neuralgia, Atypical0low10
Neuralgia, Iliohypogastric Nerve0low10
Neuralgia, Ilioinguinal0low10
Neuralgia, Perineal0low10
Neuralgia, Stump0low10
Neuralgia, Supraorbital0low10
Neuralgia, Vidian0low10
Neuritis0low10
Neuritis, Motor0low10
Neuritis, Peripheral0low10
Neuritis, Sensory0low10
Neuroborreliosis, Borrelia burgdorferi0low10
Neurodynia0low10
Neurogenic Inflammation0low10
Neuropathic Pain0low10
Osteoporosis0low20
Osteoporosis, Age-Related0low20
Osteoporosis, Involutional0low20
Osteoporosis, Post-Traumatic0low20
Osteoporosis, Senile0low20
Pain0low100
Pain, Burning0low100
Pain, Crushing0low100
Pain, Migratory0low100
Pain, Radiating0low100
Pain, Splitting0low100
Pancreatic Parenchyma with Edema0low10
Pancreatic Parenchymal Edema0low10
Pancreatitis0low10
Pancreatitis, Acute0low10
Pancreatitis, Acute Edematous0low10
Paroxysmal Nerve Pain0low10
Peripancreatic Fat Necrosis0low10
Peripheral Nervous System Lyme Disease0low10
Poisoning, Blood0low10
Polyarthritis0low10
Polyneuritis0low10
Post-Traumatic Myelopathy0low20
Pruritis0low20
Pruritus0low20
Pyaemia0low10
Pyemia0low10
Pyohemia0low10
Reperfusion Injury, Myocardial0low10
Sciatic Nerve Diseases0low10
Sciatic Nerve Palsy0low10
Sciatic Neuritis0low10
Sciatic Neuropathy0low10
Senile Osteoporosis0low20
Sensitivity, Contact0low10
Sepsis0low10
Septicemia0low10
Severe Sepsis0low10
Skin and Subcutaneous Tissue Disorders0low10
Skin Diseases0low10
Spinal Cord Contusion0low20
Spinal Cord Injuries0low20
Spinal Cord Laceration0low20
Spinal Cord Transection0low20
Spinal Cord Trauma0low20
Suffering, Physical0low100
Tactile Allodynia0low70
Temporomandibular Disorders0low20
Temporomandibular Joint Diseases0low20
Temporomandibular Joint Disorders0low20
Thermal Allodynia0low70
TMJ Diseases0low20
TMJ Disorders0low20